Omics Technology facility

核心技术开发一直是本财年的主要重点。我们正在建立基于NGS的技术，以发现癌症驱动因素，并了解生物学机制。具体地说，以下技术已经建立或即将建立。1.用于癌症突变检测的NGS。我们采用了DNA和RNA外显子组测序的方法，目的是检测SNV、缺失和插入。2.NGS用于表达和融合检测。实验室的工作人员接受了RNA外显子序列的培训，以检测融合和进行表达分析。3.表观遗传调控。我们采用了两种不同的CHIP-SEQ方法，包括抗体介导的微球菌核酸酶切割DNA和转座。4.癌症基因面板的定向测序5.针对肿瘤抗原的T细胞介导反应中涉及的基因的定制分析开发和测序6.验证NGS方法的预期研究或临床应用，7.完善NGS数据分析的分析流水线。8.使用FISH、RNAScope和其他基于荧光的方法研究肿瘤的异质性。

Core technology development has been the main focus during this fiscal year. We are in the process of establishing NGS-based technologies for the discovery of cancer drivers, and for understanding biological mechanisms. Specifically, the following technologies are established or near establishment. 1. NGS for cancer mutation detection. We adapted methods for both DNA and RNA Exome sequencing aimed for detection SNV, deletion, an insertion. 2. NGS for expression and fusion detection. The staff in the lab were trained for RNA Exome seq for the detection of fusions, and for expression analysis. 3. Epigenetic regulation. We adapted two different methods for chip-seq, including antibody-mediated DNA cutting by micrococcal nucleases and transposes. 4. Targeted sequencing of cancer gene panels 5. Customized assay development and sequencing of genes involved in T-cell mediated responses against tumor antigens 6. Validation of the NGS methods for their intended research or clinical use, respectively 7. Refining the analytical pipelines for NGS data analysis. 8. Investigating tumor heterogeneity using FISH, RNAScope, and other fluorescent based methods.